The Use of Nucleoside Reverse Transcriptase Inhibitors Sparing Regimens in Treatment-Experienced HIV-1 Infected Patients

Author(s): Antonio Di Biagio, Elena Ricci, Claudio Viscoli, Alessio Mesini, Barbara Menzaghi, Laura Carenzi, Giancarlo Orofino, Giustino Parruti, Canio Martinelli, Giordano Madeddu, Giuseppe Vittorio De Socio, Marco Franzetti, Tiziana Quirino, Paolo Paolo Bonfanti on behalf of the CISAI Group

Journal Name: Current HIV Research
HIV and Viral Immune Diseases

Volume 11 , Issue 3 , 2013


Become EABM
Become Reviewer
Call for Editor

Abstract:

Despite the relative lack of data, nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-sparing regimens are increasingly prescribed in clinical practice in treatment-experienced HIV-1 infected patients. We aimed to assess the frequency of NRTI-sparing regimens among these subjects, and to evaluate and compare their safety and tolerability. Patients were included if enrolled in the currently ongoing cohorts (raltegravir and darunavir) of the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) Project. The duration of treatment with antiretroviral therapy was evaluated using the Kaplan-Meier curve and NRTI-sparing and NRTI-based regimens were compared using the log-rank test. From 2006 to 2011, 689 experienced patients were analyzed, of whom 210 (30.5%) were on NRTI-sparing regimens. Patients on NRTI-sparing regimens were older (p=0.004) and had higher median CD4+ cell counts (p=0.002) than patients on NRTI-based regimens. The most frequent combination regimens were raltegravir plus darunavir/ritonavir (n=65; 30.95%) among patients on NRTI-sparing regimen and tenofovir DF/emtricitabine plus darunavir/ritonavir in the NRTI-containing group (n=102; 21.3%). There was no difference between groups in terms of total withdrawal, treatment discontinuation was more likely due to therapeutic failure in NRTI-sparing regimen. NRTI-sparing regimens should be evaluated in a prospective randomized trial.

Keywords: Antiretroviral therapy, darunavir, durability, NRTI-sparing regimen, raltegravir, safety.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 11
ISSUE: 3
Year: 2013
Page: [179 - 186]
Pages: 8
DOI: 10.2174/1570162X113119990036
Price: $65

Article Metrics

PDF: 21